Did Eli Lilly Just Get a Leg Up on Novo Nordisk?

Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.Pharmaceutical giant Eli Lilly (LLY 1.53%) has gotten off to an incredible start in 2024.The company's diabetes and obesity care treatments, Mounjaro and Zepbound, continue to support unprecedented growth for Lilly in a heated race with its rival Novo Nordisk, the maker of glucagon-like peptide 1 (GLP-1) agonists Ozempic, Wegovy, Rybelsus, and Saxenda.Although GLP-1 medications are in the spotlight for Lilly, investors should be keen to ...